MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma
Background: Tumor mutational burden (TMB) has emerged as an independent biomarker to predict patient responses to treatment with immune checkpoint inhibitors (ICIs) for lung adenocarcinoma (LUAD). MicroRNAs (miRNAs) have a crucial role in the regulation of anticancer immune responses, but the associ...
Main Authors: | Yufeng Lv, Zhong Huang, Yan Lin, Yuan Fang, Zhichao Chen, Lili Pan, Yanxian Zhang, Zihai Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-10-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2019.1629260 |
Similar Items
-
Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
by: Mingming Jia, et al.
Published: (2020-02-01) -
The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
by: Yongfeng Wu, et al.
Published: (2020-04-01) -
A Combined Two-mRNA Signature Associated With PD-L1 and Tumor Mutational Burden for Prognosis of Lung Adenocarcinoma
by: Congkuan Song, et al.
Published: (2021-01-01) -
Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma
by: Ying Li, et al.
Published: (2020-01-01) -
Mutational analysis on gastric, duodenal, bone, and mediastinal lymph node metastases and blood from a case of primary lung adenocarcinoma
by: Yang X, et al.
Published: (2018-07-01)